FDA Panel Backs New mRNA Flu Vaccine After Recent Controversy

A group of independent health experts has voted to support a new flu vaccine created by Moderna. On Thursday, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) held an all-day meeting to review the vaccine, which is known as mFlusiva. The committee voted 9–0 to endorse the vaccine, stating that its benefits for adults aged 50 and older are greater than its potential risks.

This vote is a significant step for the vaccine, which recently faced a difficult path to review. Earlier this year, the Food and Drug Administration (FDA) briefly refused to accept the application for the vaccine. According to STAT News, a top official at the agency initially blocked the review, claiming that the company had not compared its vaccine against the best available options for older adults. However, the agency later changed its position after Moderna provided more data and agreed to perform further studies after the vaccine is released to the public.

The vaccine uses mRNA technology, the same method used to create highly effective COVID-19 shots. While this technology is well-known, it has recently faced criticism from some government leaders. MedPage Today reports that Robert F. Kennedy Jr., the current Secretary of Health and Human Services, has previously expressed concerns about mRNA technology and even cancelled federal funding for related research. Despite this, the panel of experts highlighted the clear advantages of using this platform for seasonal flu protection.

During the meeting, experts pointed to the vaccine’s strong performance in clinical trials. Data from a large study of over 40,000 adults aged 50 and older showed that the mRNA vaccine was about 27 percent more effective than standard flu shots. For those aged 65 and older, the results were even more promising. This group is particularly important because, according to CDC estimates cited by MedPage Today, people over 65 account for the majority of flu-related hospitalizations and deaths in the United States.

Flor Munoz-Rivas, a member of the advisory committee and a pediatric infectious disease expert at Baylor College of Medicine, praised the study results. She noted that the data was very clear and showed that the vaccine provides meaningful extra protection. She also highlighted that the mRNA platform allows scientists to develop vaccines much faster. This speed is essential for preparing for new, emerging strains of the flu or even future pandemics, she explained.

Other experts highlighted different benefits of the new technology. Hayley Gans, a doctor at Stanford Medicine Children's Health, noted that the vaccine appears to create a better T-cell response. T-cells are a vital part of the body’s immune system that help fight off infections. Gans explained that current flu vaccines often struggle to keep immunity levels high, but this new mRNA approach could offer longer-lasting protection.

Despite the positive vote, some members of the panel noted that the research had limitations. Adam Berger, a scientist from the National Institutes of Health, pointed out that the main study only looked at one flu season. He also noted that there is not yet enough data on how the vaccine works in people who are very frail or have weak immune systems. However, Berger concluded that the evidence was strong enough to suggest that the vaccine will be effective in the real world.

Moderna is now seeking two types of approval from the FDA. For adults aged 50 to 64, the company is asking for traditional approval. For those 65 and older, they are seeking an accelerated approval — a process that allows for faster access to medicines that treat serious conditions. To support this, Moderna has promised to conduct a large, multi-year study to compare the vaccine’s effectiveness in the real world.

While the committee’s vote is not the final step, it is a major signal of support. The FDA usually follows the advice of its expert panels, though it is not required to do so. If the agency gives its final approval, it would mark a change in how the U.S. approaches annual flu prevention. As the country looks toward future flu seasons, this new technology could become a primary tool in protecting the health of older Americans.